CLSK
CleanSpark, Inc.
There isn't enough reported data to score CLSK yet.
NVDA
NVIDIA Corporation
NVDA's fundamentals are strong and it looks cheap: trading at 21x earnings, about a third of its usual 65x. Analysts expect strong earnings growth.
CLSK Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Unavailable | |
| Weak |
CLSK's revenue is currently healthy, but its profitability and balance sheet are weak. There isn't enough data to rate its cash flow.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
CLSK PE Valuation
CLSK has no meaningful PE right now: it lost money over the past year.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
CLSK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect CLSK's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
NVDA has the edge over CLSK on the outlook, with more favorable earnings and revenue expectations.
CLSK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$3.80 | -614% |
| Q1 2026 | -$2.09 | -$1.02 |
| Q4 2025 | -$1.06 | -$1.06 |
| Q3 2025 | $1.12 | +$1.81 |
| Q2 2023 | -$1.77 | -$1.25 |
| Q1 2023 | -$2.36 | -$2.06 |
| Q4 2022 | -$2.13 | -$2.05 |
| Q3 2022 | -$1.35 | -$0.60 |
CLSK has swung to a loss: it lost $3.80 per share over the past year, after a profit the year before.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over CLSK on earnings quality, reporting a profit while its opponent remains loss making.
CLSK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2024 | $89.3M | +70% |
| Q2 2024 | $104.1M | +129% |
| Q1 2024 | $111.8M | +163% |
| Q4 2023 | $73.8M | +165% |
| Q3 2023 | $52.5M | +101% |
| Q2 2023 | $45.5M | +47% |
| Q1 2023 | $42.5M | +2.2% |
| Q4 2022 | $27.8M | -33% |
NVDA has the stronger quarterly revenue trend. Revenue is up 70% for CLSK versus up 106% for NVDA.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2024 | -73% | +58 points |
| Q2 2024 | -239% | -205 points |
| Q1 2024 | 123% | +164 points |
| Q4 2023 | 39% | +143 points |
| Q3 2023 | -132% | +24 points |
| Q2 2023 | -34% | +14 points |
| Q1 2023 | -41% | -49 points |
| Q4 2022 | -104% | -115 points |
CLSK's operating margin was −73% last quarter, up 58 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA's revenue has grown year over year for 13 quarters in a row: $96.2B last quarter, up 106% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA's operating margin was 66% last quarter, up 5.4 points from the same quarter a year ago, near the top of its range since 2019.
CLSK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$118.4M | -$8.5M |
| Q1 2026 | -$173.4M | -$61.1M |
| Q4 2025 | -$198.1M | -$78.6M |
| Q2 2025 | -$109.9M | -$31.5M |
| Q1 2025 | -$112.3M | -$53.9M |
| Q4 2024 | -$119.5M | -$51.9M |
| Q3 2024 | -$95.5M | -$32.7M |
| Q2 2024 | -$78.3M | -$59.1M |
NVDA has the stronger cash trend. Its trailing FCF is up 290% versus its history, compared with CLSK at down 283%.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA's free cash flow has been positive every quarter for six years: $127B over the past year, up 76% from the year before.
CLSK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.1% | -11M shares |
| 1 year | -21% | -68.8M shares |
| 3 years | +287% | +190M shares |
| 5 years | +4901% | +252M shares |
CLSK has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $460M |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $145M |
CLSK spent $460M buying back its own shares over the past year.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
CLSK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 150.4x | High |
| Q4 2025 | 7.4x | High |
| Q3 2025 | 0.9x | Very low |
| Q2 2025 | 1.1x | Healthy |
| Q4 2024 | 1.6x | Healthy |
| Q3 2024 | -20.5x | Net Cash |
| Q2 2024 | -14.8x | Net Cash |
| Q1 2024 | -1.4x | Net Cash |
CLSK's net debt is more than 20 years of its operating earnings (EBITDA), up from 1.6 years a year ago.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over CLSK on leverage, with a lower net debt burden relative to earnings.
CLSK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 8.2 | Oversold |
CLSK's weekly RSI is 34 (neutral) and its Stochastic is 8 (oversold).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
CLSK PE vs Technology Sector
| Metric | CLSK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
CLSK has no meaningful PE right now: it lost money over the past year.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
CLSK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.27 | 26% below |
| 20 week MA | $11.5 | 40% below |
| 50 week MA | $12.0 | 43% below |
| 100 week MA | $11.5 | 41% below |
| 200 week MA | $10.5 | 35% below |
CLSK is in a downtrend: it's below all five of its weekly moving averages, and 35% below its 200-week average.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has the edge over CLSK on trend strength, trading above more of its moving averages.
CLSK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.2 | $24.9 | +54% |
| 2021 | $24.9 | $11.9 | -52% |
| 2022 | $11.9 | $1.97 | -83% |
| 2023 | $1.97 | $11.0 | +460% |
| 2024 | $11.0 | $9.78 | -11% |
| 2025 | $9.78 | $10.9 | +12% |
| 2026 YTD | $10.9 | $6.84 | -37% |
CLSK's yearly returns have swung widely, from +460% in 2023 to −83% in 2022. It's down 37% so far in 2026.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over CLSK on returns for 2026, with the stronger performance.